• Government-led national program in Morocco to support early autism screening
• Systematic screening to be implemented nationwide starting at 18 months of age
• BlinkLab's Dx 1 technology selected to be integrated into the screening program

BlinkLab Limited (ASX:BB1) has announced its involvement in a landmark national autism screening and capacity-building initiative launched by the Kingdom of Morocco. This is the first and most comprehensive of its kind worldwide, positioning Morocco as a leading example for the international community. The nationwide screening program is being launched pursuant to the High Instructions of His Majesty King Mohammed VI and reflects Morocco's national commitment to equitable access to healthcare, education, and social services for persons with disabilities. BlinkLab's flagship Dx 1 technology has been selected to support the initiative, which will implement systematic early autism screening commencing from 18 months of age across the country. The program will integrate validated digital screening tools across primary care, community, and specialist settings, and develop a specialized clinical training program in Applied Behaviour Analysis (ABA). All costs for clinical rollout and implementation will be funded by the Moroccan government and the Foundation Mohammed V for Solidarity. BlinkLab will own the data generated by the program and will provide the Foundation with access to its smartphone-based neurobehavioral assessments, as well as expertise, technical support, and training for designated staff at participating centers. The program is designed to prioritize large-scale adoption and utilization at this stage, and commercial terms, including pricing and deployment models, are expected to be revisited with Moroccan government stakeholders after any future FDA clearance.

The Moroccan government-funded autism screening program is not intended to generate immediate revenue for BlinkLab. All program-related costs, including infrastructure, hardware, data storage, and implementation expenses, will be funded by the Moroccan government and associated Foundation partners. No material capital expenditure is expected to be borne by BlinkLab as part of this initiative.

The engagement in the Moroccan government-led national autism screening and training framework constitutes a significant real-world validation opportunity that complements BlinkLab's ongoing FDA registrational clinical trial program in the US. A successful outcome to these programs will provide the clinical validation required to support commercialization and the ability of BlinkLab's technology to integrate with national public health systems where scalability, operational reliability, and standardized delivery are fundamental requirements. The Moroccan program has also been explicitly designed with a broader regional outlook, providing a structured, government-endorsed model that can be referenced by other countries across North Africa and the Middle East.